Jove
Visualize
Contact Us

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
T Cell Types and Functions01:24

T Cell Types and Functions

961
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
961
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Ticrr Overexpression Enhances Disease Aggressiveness And Immune Infiltration Of Cutaneous Melanoma.
  1. Home
  3. Ticrr Overexpression Enhances Disease Aggressiveness And Immune Infiltration Of Cutaneous Melanoma.

Related Experiment Video

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K

TICRR Overexpression Enhances Disease Aggressiveness and Immune Infiltration of Cutaneous Melanoma.

Cheng Chen1, Yong Zou1, Xiangbing Zheng1

  • 1Department of Burn and Plastic Surgery, The Second People's Hospital of Yibin (West China Yibin Hospital, Sichuan University), Yibin, Sichuan, People's Republic of China.

Pharmacogenomics and Personalized Medicine
|September 9, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

TopBP1 interacting checkpoint and replication regulator (TICRR) is overexpressed in cutaneous melanoma (CM), worsening prognosis. Suppressing TICRR inhibits CM cell growth and migration, suggesting it as a potential therapeutic target.

Keywords:
TICRRcutaneous melanomaimmune infiltrationinvasionprognosis

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

808
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.1K

Related Experiment Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.3K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

808
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.1K

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Cutaneous melanoma (CM) is a significant public health concern.
  • Identifying novel prognostic biomarkers and therapeutic targets for CM is crucial.

Purpose of the Study:

  • To investigate the role of TopBP1 interacting checkpoint and replication regulator (TICRR) in CM.
  • To evaluate TICRR as a prognostic biomarker and therapeutic target for CM.

Main Methods:

  • TICRR expression analysis using TCGA and GTEx databases.
  • Kaplan-Meier survival analysis, nomogram, and risk score modeling.
  • In vitro experiments to assess TICRR's effect on CM cell aggressiveness and underlying mechanisms.
  • Immune cell infiltration analysis.

Main Results:

  • TICRR is overexpressed in CM and correlates with poor prognosis.
  • TICRR knockdown reduces CM cell proliferation, migration, and invasion.
  • TICRR suppression attenuates PI3K/AKT/mTOR signaling.
  • TICRR is associated with increased immune cell infiltration.

Conclusions:

  • TICRR overexpression enhances CM aggressiveness by activating PI3K/AKT/mTOR signaling and promoting immune infiltration.
  • TICRR serves as a potential prognostic biomarker and therapeutic target for CM.